Abstract
IntroductionChronic plaque psoriasis is an inflammatory skin disorder that affects 2–3% of the population. The severity of the disease is influenced by the number and location of skin lesions, concomitant conditions such psoriatic arthritis, and the impact on daily life. Several comorbidities, such as depression, cardiometabolic disorders, and psoriatic arthritis, are linked to plaque psoriasis. Hence, aim of current review is to highlight the comprehensive information on the pathophysiology, mechanism of action of recent approved drugs and future prospective. Further, clinical research and lengthy prospective cohort studies have been discussed. Materials and methodsThe data were collected from the various reported literatures PubChem, scopus and other search engines which are suggesting for the management of plaque psoriasis. These literature review were selected based on the current updated treatment of chronic plaque psoriasis. ResultVarious biologics have been promoted by the National Psoriasis Foundation guidelines as a first-line treatment option for moderate to severe plaque psoriasis due to their effectiveness in treating the condition and their acceptable safety profiles. The aryl hydrocarbon receptor (AhR) modulator tapinarof, the phosphodiesterase-4 (PDE4) inhibitor roflumilast and the tyrosine kinase 2 (TYK2) inhibitor deucravacitinib are the new drugs approved by US Food and Drug Administration (FDA) for promising treatment mild-severe plaque psoriasis. DiscussionsThe conventional systemic therapy for treatment of plaque psoriasis was found to be unsatisfactory due to several significant adverse effects and contraindications. It is vital to continue developing efficacious, safe, and tolerant systemic medication approach capable of being employed as first-line systemic treatments for those with moderate-to-severe psoriasis. The recent approved drugs by USFDA for the management of psoriasis offer the potential for enhanced efficacy and better disease control.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
